STOCK TITAN

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

JAZZ NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
6 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+13.2% close of February 25, 2026
1-year change
+41.5% closing prices, November 17, 2025 to November 17, 2026
1-month change
+14.5% closing prices, October 16, 2026 to November 17, 2026

Company Description

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for people with serious diseases, often where there are limited or no therapeutic options. According to company disclosures, Jazz has a diverse portfolio of marketed medicines, including therapies for sleep disorders, epilepsy and a growing range of oncology treatments. The company emphasizes a patient-focused and science-driven approach, using clinical research and real-world evidence to inform its development programs.

Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research and development laboratories, manufacturing facilities and employees in multiple countries. Its ordinary shares trade on The Nasdaq Stock Market LLC under the symbol JAZZ, as noted in its SEC filings. Through its global footprint, Jazz states that it is committed to serving patients and families worldwide.

Core therapeutic areas

Jazz reports that its portfolio includes leading therapies for sleep disorders and epilepsy, as well as cancer treatments across several oncology indications. In neuroscience, the company highlights products such as Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for narcolepsy and idiopathic hypersomnia, and Epidiolex/Epidyolex (cannabidiol) oral solution for rare, treatment-resistant epilepsies including Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) and tuberous sclerosis complex (TSC). These medicines are supported by ongoing Phase 4 trials and real-world evidence programs designed to better understand clinical outcomes, comorbidities and treatment patterns.

In oncology, Jazz is advancing therapies in both hematologic and solid tumors. The company describes a growing portfolio of cancer treatments and an expanding clinical program in HER2-driven cancers and central nervous system (CNS) tumors. Ziihera (zanidatamab-hrii), a bispecific HER2-directed antibody, is indicated in the United States for previously treated, unresectable or metastatic HER2-positive biliary tract cancer. Jazz is also developing Ziihera in multiple Phase 2 and Phase 3 trials in HER2-positive gastroesophageal adenocarcinoma (GEA), biliary tract cancer and breast cancer. In neuro-oncology, Modeyso (dordaviprone) is approved in the U.S. for H3 K27M-mutant diffuse midline glioma in adult and pediatric patients one year of age and older with progressive disease following prior therapy.

Neuroscience: sleep disorders and epilepsy

Jazz positions itself as a significant participant in sleep medicine and epilepsy. The company sponsors clinical and real-world studies to evaluate outcomes with Xywav in narcolepsy and idiopathic hypersomnia. Data presented at international congresses have examined sleep architecture, daytime sleepiness, sleep inertia, cardiovascular and cardiometabolic risks associated with sodium intake, and the impact of switching from high-sodium oxybate to low-sodium oxybate regimens.

In epilepsy, Jazz focuses on rare and severe seizure disorders. Epidiolex/Epidyolex (cannabidiol) is described as a plant-derived, highly purified cannabidiol oral solution. In the U.S., Epidiolex is indicated for seizures associated with LGS, DS or TSC in patients one year of age and older. In the European Union, under the tradename Epidyolex, it is approved as adjunctive therapy in conjunction with clobazam for LGS and DS in patients two years and older, and as adjunctive therapy for TSC-associated seizures in patients two years and older. Jazz continues to generate evidence through Phase 3b/4 trials and real-world analyses, including studies on behavioral and non-seizure outcomes, polypharmacy, healthcare resource utilization and pharmacokinetic interactions with other antiseizure medications.

Oncology and HER2-targeted therapies

Oncology is another major pillar of Jazz Pharmaceuticals' business. The company highlights Ziihera (zanidatamab-hrii) as a bispecific HER2-directed antibody that binds two extracellular sites on HER2, leading to receptor internalization and reduction in HER2 expression on tumor cells. Ziihera is reported to induce complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, resulting in tumor growth inhibition and cell death in preclinical models.

Ziihera has U.S. accelerated approval for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, based on overall response rate and duration of response. Jazz, together with partners, is conducting multiple clinical trials to expand the clinical profile of Ziihera, including the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, Phase 3 HERIZON-BTC-302 in biliary tract cancer, and trials in metastatic and early-stage HER2-positive breast cancer and other HER2-expressing solid tumors.

Neuro-oncology and rare brain tumors

Jazz is also active in neuro-oncology, particularly in rare and aggressive brain tumors. Modeyso (dordaviprone), formerly known as ONC201, is described as a mitochondrial caseinolytic protease P (ClpP) agonist and dopamine-2 receptor inhibitor. It is administered orally once weekly and is approved in the United States for H3 K27M-mutant diffuse midline glioma in adult and pediatric patients one year of age and older with progressive disease following prior therapy. Jazz reports that dordaviprone has been shown in vitro to activate the integrated stress response, alter mitochondrial metabolism and restore histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.

The company supports ongoing clinical and translational research on Modeyso, including the Phase 3 ACTION trial in newly diagnosed H3 K27M-mutant diffuse glioma following radiotherapy, as well as preclinical work on JZP3507 (formerly ONC206) in central nervous system tumors. Presentations at scientific meetings have explored molecular pathways associated with sensitivity to dordaviprone, potential immunomodulatory effects and combination strategies.

Regulatory and corporate profile

Jazz Pharmaceuticals plc is incorporated in Ireland and identified in SEC filings with Commission File Number 001-33500 and an Irish tax registration number. The company files periodic and current reports with the U.S. Securities and Exchange Commission, including Form 8-K filings on material events such as clinical trial results, financial results, corporate governance changes and legal settlements. Its ordinary shares, with a nominal value of $0.0001 per share, are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on Nasdaq under the symbol JAZZ.

Recent SEC filings describe events such as positive top-line Phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma, financial results for quarterly periods, changes in executive leadership and board composition, and a global settlement agreement resolving patent and antitrust disputes related to oxybate therapies. These disclosures provide investors with information on Jazz’s clinical, financial and legal developments.

Research, development and scientific engagement

Across its portfolio, Jazz emphasizes research and development in oncology and neuroscience. The company regularly presents data at major medical congresses, including the European Epilepsy Congress, American Epilepsy Society Annual Meeting, World Sleep Congress, Psych Congress, American Society of Clinical Oncology Gastrointestinal Cancers Symposium and the Society for Neuro-Oncology Annual Meeting. Topics span Phase 3 and Phase 4 clinical trials, real-world evidence analyses, pharmacokinetic and pharmacodynamic interaction studies, and translational research.

By focusing on serious diseases such as narcolepsy, idiopathic hypersomnia, rare epilepsies, HER2-positive cancers and H3 K27M-mutant diffuse midline glioma, Jazz Pharmaceuticals positions its pipeline and marketed products toward areas of high unmet medical need. The company’s disclosures highlight the use of both randomized controlled trials and real-world data to evaluate treatment outcomes, safety profiles and broader impacts on patients and caregivers.

Investor considerations

Investors analyzing JAZZ stock can refer to the company’s SEC filings for details on financial performance, risk factors, legal proceedings, corporate governance and capital allocation decisions. Form 8-K filings provide updates on material events, while other periodic reports offer additional context on operations and strategy. Because Jazz operates in highly regulated therapeutic areas and focuses on serious conditions, regulatory approvals, clinical trial outcomes and intellectual property developments are central to its business profile as presented in public disclosures.

Stock Performance

$240.71
+0.39%
+0.94
Last updated: at
+41.5%
Performance 1 year
$15.5B

Jazz Pharmaceuticals (JAZZ) closed at $240.71 on November 17, 2026. Over the past 12 months, the price has gained 41.5%.

See what a $1,000 investment in JAZZ would be worth today

Average down calculator for JAZZ

JAZZ Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Jazz Pharmaceuticals has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include conferences, earnings, clinical trial, earnings date, management. View all JAZZ news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
171,342
Shares Sold
19
Transactions
Most Recent Transaction
COZADD BRUCE C (Director) sold 68,808 shares at an average of $235.95 on November 6, 2026

Insider selling at Jazz Pharmaceuticals over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Jazz Pharmaceuticals generated $4.3B in revenue in FY2025, operating income reached -$430.2M (-10.1% operating margin), and net income was -$356.1M, reflecting a -8.3% net profit margin. Diluted earnings per share stood at -$5.84. The company generated $1.4B in operating cash flow. The current ratio was 1.86, measuring current assets divided by current liabilities.

$4.3B
Revenue (FY2025)
-$356.1M
Net Income (FY2025)
$1.4B
Operating Cash Flow

Upcoming Events

NOV
17
November 17, 2026 Marketing

Jefferies fireside chat

Jefferies London Global Healthcare fireside chat Nov 17 8:00 AM ET; audio webcast on Jazz investor website; replays archived 30 days.
DEC
02
December 2, 2026 Marketing

Piper Sandler chat

Piper Sandler 38th Annual Healthcare fireside chat Dec 2 8:00 AM ET; audio webcast on Jazz investor site; replay available 30 days.
DEC
02
December 2, 2026 Marketing

Citi fireside chat

Citi 2026 Global Healthcare fireside chat Dec 2 3:00 PM ET; audio webcast on Jazz investor website; replays archived for 30 days.
H1
2027
H1 2027 Clinical

ACTION interim analysis

Planned interim analysis of the Phase 3 ACTION trial (Modeyso) expected in H1 2027; key to accelerated-approval verification.
SEP
15
September 15, 2032 Financial

Notes maturity

Maturity of $1.1B 1.875% exchangeable senior notes due 2032 issued by Jazz Investments I Limited, guaranteed by Jazz.

Jazz Pharmaceuticals has 5 upcoming scheduled events. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the JAZZ stock price.

Short Interest History

Last 12 Months

Short interest in Jazz Pharmaceuticals (JAZZ) currently stands at 5.8 million shares, down 1.1% from the previous reporting period, representing 9.4% of the float. Since November 2025, short interest has increased by 16.6%.

Days to Cover History

Last 12 Months

Days to cover for Jazz Pharmaceuticals (JAZZ) currently stands at 7.7 days, up 11.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 242.4%. Across the settlements charted above, it has ranged from 2.2 to 9.1 days.

JAZZ Company Profile & Sector Positioning

Jazz Pharmaceuticals (JAZZ) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing JAZZ often look at related companies in the same sector, including Exelixis Inc (EXEL), BridgeBio Pharma, Inc. (BBIO), Ascendis Pharma A/S (ASND), Summit Therapeutics Inc. (SMMT), and BioMarin Pharmaceuticals Inc (BMRN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate JAZZ's relative position within its industry.

Frequently Asked Questions

The current stock price of Jazz Pharmaceuticals (JAZZ) is $240.71 as of November 17, 2026.

The market cap of Jazz Pharmaceuticals (JAZZ) is approximately $15.5B. Learn more about what market capitalization means .

The FY2025 revenue of Jazz Pharmaceuticals (JAZZ) is $4.3B, from its most recent completed fiscal year.

The FY2025 net income of Jazz Pharmaceuticals (JAZZ) is -$356.1M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Jazz Pharmaceuticals (JAZZ) is -$5.84 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Jazz Pharmaceuticals (JAZZ) is $1.4B for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Jazz Pharmaceuticals (JAZZ) is -8.3% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Jazz Pharmaceuticals (JAZZ) is -10.1% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Jazz Pharmaceuticals (JAZZ), current assets divided by current liabilities, was 1.86 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Jazz Pharmaceuticals (JAZZ) is -$430.2M for FY2025, its most recent completed fiscal year. Learn about operating income.

Jazz Pharmaceuticals plc is a global biopharma company that develops and commercializes medicines for people with serious diseases, often where there are limited or no therapeutic options. According to its public statements, Jazz has a diverse portfolio of marketed medicines for sleep disorders, epilepsy and cancer, supported by ongoing clinical and real-world research in oncology and neuroscience.

Jazz Pharmaceuticals highlights two main areas: neuroscience and oncology. In neuroscience, it focuses on sleep disorders such as narcolepsy and idiopathic hypersomnia and on rare epilepsies including Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. In oncology, it is active in HER2-driven cancers, biliary tract cancer, gastroesophageal adenocarcinoma, breast cancer and rare central nervous system tumors such as H3 K27M-mutant diffuse midline glioma.

Jazz Pharmaceuticals plc is headquartered in Dublin, Ireland. Its ordinary shares are registered under Section 12(b) of the Securities Exchange Act of 1934 and trade on The Nasdaq Stock Market LLC under the ticker symbol JAZZ, as indicated in the company’s SEC filings.

Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody developed under license agreements and marketed by Jazz Pharmaceuticals. It is indicated in the United States for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. Jazz is also evaluating Ziihera in multiple clinical trials, including Phase 3 studies in first-line HER2-positive gastroesophageal adenocarcinoma and other HER2-driven solid tumors, making it a key component of the company’s oncology portfolio.

Epidiolex/Epidyolex (cannabidiol) is a plant-derived, highly purified cannabidiol oral solution that Jazz describes as part of its epilepsy portfolio. In the U.S., Epidiolex is indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in patients one year of age and older. In the European Union, under the tradename Epidyolex, it is approved as adjunctive therapy for LGS, DS and TSC-associated seizures in specified age groups. Jazz supports this medicine with ongoing Phase 3b/4 trials and real-world evidence studies.

Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is described by Jazz Pharmaceuticals as a low-sodium oxybate therapy. It is approved by the U.S. Food and Drug Administration for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy 7 years of age and older, and for idiopathic hypersomnia in adults. Jazz has presented Phase 4 and real-world data on Xywav’s effects on sleep measures, daytime functioning and cardiovascular considerations related to sodium intake.

Modeyso (dordaviprone), formerly known as ONC201, is an oral small molecule developed for H3 K27M-mutant diffuse midline glioma. Jazz reports that it is approved in the United States for adult and pediatric patients one year of age and older with progressive H3 K27M-mutant diffuse midline glioma following prior therapy. Modeyso is part of Jazz’s neuro-oncology efforts, with ongoing clinical and translational research, including the Phase 3 ACTION trial.

Jazz Pharmaceuticals describes its approach as patient-focused and science-driven. The company emphasizes the use of Phase 3 and Phase 4 clinical trials, as well as real-world evidence, to understand treatment outcomes, safety and broader impacts on patients and caregivers. It regularly presents data at international congresses in epilepsy, sleep medicine, oncology and neuro-oncology, reflecting a focus on serious diseases with high unmet medical need.

Jazz Pharmaceuticals’ SEC filings, including Form 8-K current reports, provide information on material events such as clinical trial results, financial results, executive and board changes, legal settlements and other corporate developments. These filings also confirm that its ordinary shares are listed on Nasdaq under the symbol JAZZ and provide details on the company’s jurisdiction of incorporation, registered securities and certain governance matters.

Yes. Jazz Pharmaceuticals describes itself as a global biopharma company headquartered in Dublin, Ireland, with research and development laboratories, manufacturing facilities and employees in multiple countries. Its marketed medicines, including therapies for sleep disorders, epilepsy and cancer, are used in various regions subject to local regulatory approvals.